Methyl-1 orthotolyl-2 pyrrolidine | 46154-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: Methyl-1 orthotolyl-2 pyrrolidine
• 英文别名: 1-Methyl-2-o-tolyl-pyrrolidin；1-methyl-2-o-tolyl-pyrrolidine；1-methyl-2-(2-methylphenyl)pyrrolidine
• CAS: 46154-92-1
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: JRZMWCKLABIBLI-UHFFFAOYSA-N

物化性质

• 沸点：
  104 °C(Press: 8.5 Torr)
• 密度：
  0.972±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Methyl-1 orthotolyl-2 pyrrolidine 、 rac-tartaric acid dibenzoate 生成 2,3-dibenzoyloxybutanedioic acid;1-methyl-2-(2-methylphenyl)pyrrolidine
  参考文献：
  名称：

  CERVINKA, O.;SEDLAK, I.;STREJCEK, F., COLLECT. CZECH. CHEM. COMMUN., 1983, 48, N 6, 1618-1623

  摘要：

  DOI：
• 作为产物：
  描述：

  1-methyl-2-(2-tolyl)-1-pyrrolinium chloride 在 甲酸 、 potassium formate 作用下， 反应 4.0h， 以6.6 g的产率得到Methyl-1 orthotolyl-2 pyrrolidine
  参考文献：
  名称：

  Cervinka, Otakar; Sedlak, Ilja; Strejcek, Frantisek, Collection of Czechoslovak Chemical Communications, 1983, vol. 48, # 6, p. 1618 - 1623

  摘要：

  DOI：

文献信息

• Iridium-Catalyzed Asymmetric Hydrogenation of Cyclic Enamines
  作者：Guo-Hua Hou、Jian-Hua Xie、Pu-Cha Yan、Qi-Lin Zhou

  DOI：10.1021/ja808358r

  日期：2009.2.4

  The first highly enantioselective iridium-catalyzed hydrogenation of cyclic enamines has been developed. This new reaction provided an efficient method for the synthesis of optically active cyclic tertiary amines including natural product crispine A.

  已经开发出第一个高度对映选择性的铱催化的环状烯胺氢化。这一新反应为合成包括天然产物crispine A在内的光学活性环状叔胺提供了一种有效的方法。
• CONTROLLED RELEASE PREPARATION
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160128945A1

  公开（公告）日：2016-05-12

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.

  提供了一种受控释放制剂，其中活性成分的释放受到控制，通过在胃肠道内停留或缓慢迁移来延长时间释放活性成分，采用胶囊化片剂、颗粒或细颗粒的方式，其中活性成分的释放受到控制，并且使用了一种凝胶形成聚合物。所述的片剂、颗粒或细颗粒在含有活性成分的核心颗粒上形成了一个受控释放的涂层。
• (PYRROLIDIN-2-YL)PHENYL DERIVATIVES
  申请人：Grove Simon James Anthony

  公开号：US20100113493A1

  公开（公告）日：2010-05-06

  The invention relates to (pyrrolidin-2-yl)phenyl derivatives having the general Formula I wherein R 1 is (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy, or halo(C 1-4 )alkyloxy; R 2 is H, (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy, halo(C 1-4 )alkyloxy or halogen; R 3 is H, (C 1-4 )alkyl or halo(C 1-4 )alkyl; R 4 is H, (C 1-4 )alkyl or halo(C 1-4 )alkyl; R 5 is H, (C 1-4 )alkyl or halo-(C 1-4 )-alkyl; or R 4 and R 5 , when bonded to the same carbon atom, can together with the carbon atom form a spiro(C 3-6 )cycloalkyl group, optionally substituted with halogen; R 6 is H, (C 1-4 )alkyl, halo(C 1-4 )alkyl, (C 1-4 )alkyloxy, halo(C 1-4 )alkyloxy or halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these (pyrrolidin-2-yl)phenyl derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain.

  该发明涉及具有通式I的（吡咯啉-2-基）苯基衍生物，其中R1为（C1-4）烷基、卤代（C1-4）烷基、（C1-4）烷氧基或卤代（C1-4）烷氧基；R2为H、（C1-4）烷基、卤代（C1-4）烷基、（C1-4）烷氧基、卤代（C1-4）烷氧基或卤素；R3为H、（C1-4）烷基或卤代（C1-4）烷基；R4为H、（C1-4）烷基或卤代（C1-4）烷基；R5为H、（C1-4）烷基或卤代（C1-4）烷基；或者当R4和R5与同一碳原子结合时，它们可以与碳原子一起形成一个可选择地取代卤素的螺环（C3-6）环烷基基团；R6为H、（C1-4）烷基、卤代（C1-4）烷基、（C1-4）烷氧基、卤代（C1-4）烷氧基或卤素；或其药学上可接受的盐，以及含有这些（吡咯啉-2-基）苯基衍生物的药物组合物，以及这些（吡咯啉-2-基）苯基衍生物用于治疗疼痛，如神经痛或炎症性疼痛。
• COMT Inhibiting Methods and Compositions
  申请人：Lieber Institute for Brain Development

  公开号：US20160222011A1

  公开（公告）日：2016-08-04

  The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.

  本发明涉及一种抑制受试者中COMT酶的方法，以及公式I的化合物或其药学上可接受的盐，用于治疗由COMT介导的各种疾病，包括帕金森病和/或精神分裂症。
• METHOD FOR PRODUCING GRANULES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1852100A1

  公开（公告）日：2007-11-07

  In a production process of granules containing a biologically active substance, variation in the elution profile of the biologically active substance is reduced by heating the temperature of granules to about 50°C or higher and maintaining the temperature for about 1 minute or longer. By setting the spray speed to about 90 mg/min or more per 1 g of cores when a spray agent for a primary agent containing the biologically active substance is sprayed while spraying a binding liquid to the cores and setting the total feeding weight per unit area for a centrifugal fluidized bed coating granulation machine to about 1.5 g/cm2 or more, the variation in the elution profile of the biologically active substance from the granules is reduced.

  在含有生物活性物质的颗粒的生产过程中，通过将颗粒的温度加热至约 50°C 或更高，并保持温度约 1 分钟或更长时间，可减少生物活性物质洗脱曲线的变化。将含有生物活性物质的主剂的喷雾剂喷洒到芯上的同时，将喷雾速度设定为每 1 克芯约 90 毫克/分钟或更高，并将离心流化床包衣造粒机的单位面积总喂料重量设定为约 1.5 克/平方厘米或更高，可减少颗粒中生物活性物质洗脱曲线的变化。